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adalah secara signifikannya lebih rendah dikalangan responden lembam dan KA dan 
PPKK berbanding dengan dua lagi kumpulan. Pada masa yang sama didapati tiada 
perbezaan signifikan pendapatan responden lembam dan KA dan PPKK, dan diantara 
responden normal dan terencat akal di sekolah. Ujian phenylalanine adalah negatif bagi 
1170 responden yang diambil spot darah mereka. 
Walaupun keputusannya adalah negatif, responden kajian hanyalah 5% daripada unjuran 
penduduk mengalami terencat akal, yang tidak terlibat didalam kajian ini kerana mereka 
tidak menghadiri institusi-institusi yang di lawati. Teknik makmal yang digunakan adalah 
tepat, dan ralat telah dikenalpasti secara sistematik dan dicegah untuk memastikan 
keputusan adalah sah dan boleh dipercayai. Berdasarkan kepada keadaan dan kesudahan 
penyakit, PKU adalah masalah yang penting kepada sector kesihatan dan social, dan 
dengan itu memenuhi criteria untuk diadakan satu program saringan. 
Walaubagaimanapun, keputusan negatif yang diperolehi oleh kajian ini memerlukan 
penyiasatan lanjut dilakukan dalam masa yang terdekat ini untuk meyakinkan pihak 
berkuasa akan perlunya program ini walaupun agak mahal. Kajian ini perlu di 
panjangkan untuk melibatkan pesakit lain dan juga pesakit daripada negeri-negeri lain. 
Kemungkinan juga, adalah perlu untuk mengkaji cara-cara lain bagi menyaring PKU. 
xiii 
ABSTRACT 
THE PREVALENCE OF PHENYLKETONURIA AMONG CHILDREN WITH 
MENTAL RETARDATION IN KELANTAN 
The prevalence of phenylketonuria (PKU) in Malaysia to date is not known since no 
study has been conducted to address the subject. The objectives of this study were to 
determine the prevalence of PKU among the mentally retarded children in Kelantan, to 
determine the feasibility of carrying out a screening programme for PKU in newborns 
and to establish a method for PKU screening should the need arise later on. The study 
was a cross-sectional survey involving all the schools with special programmes for 
mentally retarded children and community- and clinic-based rehabilitation centers 
( CCRC) in Kelantan. All children listed and attended these two institutions were taken as 
the study samples. A validated questionnaire was used to obtain personal and 
socioeconomic information of the patients and their families. The questionnaire was 
collected together with the written consent for the study before the final list of 
respondents was recorded. Blood spots on filter papers were collected by a finger prick 
method using automated disposable lancet. Validation of the information in the 
questionnaire, physical examinations and blood spots collection were done at the 
respective schools and CCRC. Phenylalanine assays were done using the Bacteria 
Inhibition Assay (BIA), also known as the Guthrie method. 
The BIA method was optimized in local laboratory before it is used to test the study 
samples. A total of 24 schools and 34 CCRC were visited during the study period all over 
Kelantan. Out of 1715 respondents who returned the questionnaire and consented to take 
part in the study, only 1568 agreed to have blood spots taken and were present during the 
blood collections. Other then children with mental retardation, samples were also taken 
from normal and "lembam and last classes (lembam and LC) children. Out of the 1319 
school-based respondents, 239 (18.1%) were mentally retarded and 276 (20.9%) were 
lembam and LC. All the 396 repondents from CCRC were mentally retarded children. 
The proportion of boys was significantly higher in school-based mentally retarded, 
Iembam and LC and CCRC respondents, but lower in the normal group. The majority of 
XIV 
the respondents were malays, conforming to the population structure of Kelantan. 
Household income was significantly lower in the lembam and LC and CCRC respondents 
compared to the other two groups. Likewise, there was no significant difference in 
income between the lembam and LC and CCRC respondents, and between the nonnal 
and school-based mentally retarded respondents. The phenylalanine assays were negative 
for the 1170 respondents who had their blood spots taken. 
Although the result was negative, the study respondents constituted of only 5% of the 
projected population with mental retardation, which were not captured by this study 
because they did not attend any of the institutions visited. The laboratory technique used 
was accurate and errors had been systematically addressed and prevented to ensure the 
results were valid and reliable. Phenylketonuria, given the nature and outcome of the 
disease, is a considerable problem to both the health and social sectors, and fits the 
criteria to have a screening programme put in place. However, the negative result of this 
study requires further investigations to be conducted in the near future to convince the 
authority as to the need for such an expensive programme. This study should be extended 
to include patients not covered here and also patients in other states. Perhaps, it will also 
be beneficial to examine other methods of screening for PKU. 
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CHAPTER 1. INTRODUCTION 
1.1 MENTAL RETARDATION 
1.1.1 DEFINITION 
Mental retardation is subaverage intellectual ability present from birth or early infancy. It 
is the most common lifelong handicap in developed nations and it is likely to consume 
more professional and financial resources than any other disabling conditions (Munro et a/. 
1986). Mental retardation has traditionally been defined in terms of a threshold score on 
measurement of intelligence. An individual with an Intelligence Quotient (1. Q) score below 
a specified score would be classified as mentally retarded. However~ the definition has 
recently been expanded to include social adaptation. 
Based on Diagnostic and Statistical Manual IV of American Psychological Association, 
mental retardation means significantly subaverage general intellectual functioning existing 
concurrently with deficits in adaptive behaviour and manifested during developmental 
period, that adversely affects a child's educational performance (National Information 
Centre for Children and Youth With Disabilities, 200 I). Deficits or impainnent in adaptive 
behaviour must be in at least two of the following areas; communication, self-care, home 
living, social or interpersonal skills, use of community resources, self-directed functional 
academic skills, work, leisure health and safety. The onset of mental retardation should be 
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before the age of 18 years. Mental retardation was originally classified into four levels 
based on the IQ scores (Table 1.1 ). It was later reclassified to just two levels, mild and 
severe. However, this new definition is still controversial (Bat shaw, 1993) and has not 
been fully adopted. 
Table 1.1. The levels of mental retardation based on IQ scores. 
Level of IQ Characteristics 
Retardation Scores 
Mild 50-70 A majority of all the mentally retarded. Usually show no 
physical symptoms of abnormality. Individual with higher IQ's 
in this category can marry, maintain a family, and work in 
unskilled occupations. Abstract reasoning is difficult for those 
with the lower IQ's in this category. Capable of some 
academic learning. 
Moderate 35-49 Often lack physical coordination. Can be trained to take care 
of themselves and acquire some reading and writing skills. 
Abilities of a 4-7 -year old. Capable of living outside an 
institution with their families. 
Severe 20-34 Only a few can benefit from schooling. Can communicate 
vocally after extensive training. Most require constant 
supervision. 
Profound <20 Mental age is < 3 years old. Very limited communication. 
Require constant supervision. Can learn to walk, utter a few 
simple phrases, and feed themselves. 
. . Source: The Assoetation ofRetarded CitJZen of the Umted States (2001) . 
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1.1.2 PREVALENCE OF MENTAL RETARDATION 
Mental retardation is not a disease. Children with mental retardation become adults and 
they do learn but, slowly and with difficulty. However, for some of them, even with proper 
supervision they ended with limited achievement (The Association of Retarded Citizen of 
the United States, 2001 ). Various studies have been conducted in communities to 
detennine the prevalence of mental retardation and concluded that 3% of general 
population has mental retardation (Munro, 1986). 
Based on the 1990 census, an estimated 6.2 to 7.5 million people have mental retardation 
in the United States of America (The Association of Retarded Citizen of the United States, 
2001) of whicf\ more than 85% fall into the mild range. The ratio of males to females is 
1.6: 1 in mild retardation, but is close to unity in severe mental retardation. Another 
interesting finding is the existence of different socio-economic status in different levels of 
mental retardation. The prevalence of mild mental retardation was found to be higher in 
lower socio-economic classes whereas, no class bias exists in severe retardation (Batshaw, 
1993). 
Mild mental retardation is usually an isolated disability whereas severe retardation is often 
accompanied by associated deficits that further limit the child•s adaptive abilities and affect 
outcome. The prevalence of these associated deficits roughly correlates with the severity of 
mental retardation and include cerebral palsy, visual deficits, seizure disorders, 
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communication deficits, feeding problems, psychiatric or pervasive developmental 
disorders and attention-deficit hyperactive disorder. 
In Malaysia, the actual prevalence of mental retardation had not been reported anywhere. 
Currently, there is three governmental bodies that are involved with mentally retarded 
people: the Ministry of Health (MOH), Social and Welfare (SWD) and Education (ED) 
Departments. Based on the registration list from SWD, an estimation of28 129 people are 
mentally retarded in the year 2000 (Rashid, 2000). This estimation comprised of both 
children and adults but the exact age distributions and gender are not known. 
In the education sector, special education for the special children was first introduced in 1920 
with the opening of St. Nicholas Primary School in Melaka (Abdullah, 2000). However, it 
was not until the Cabinet Report 1979, comprehensive initiatives to cater for the education 
needs of special children really took off. Based on the report, starting from 1981, the MOH 
and Ministry of Unity and Welfare were instructed to care and provide services and training 
for the children with special needs. The Government of Malaysia has also given her 
commitments in implementing recommendations agreed in international declarations such as, 
The United Convention On the Rights of The Child (1989), Education for All (1990), 
Standard Rules on the Equalisation of Opportunities for Person With Disabilities ( 1993) and 
The Salamanca Statement (1994). Up to the year 2000, there are approximately 7,223 
children with learning disabilities including mentally retarded children, attending schools all 
over Malaysia (Abdullah, 2000) 
s 
1.1.3 THE AETIOLOGY OF MENTAL RETARDATION 
Mental retardation can be caused by any condition that impairs development of the brain 
before or during birth, or in the childhood years. Hundreds of causes have been discovered, 
but most children with mild mental retardation do not carry an etiologic diagnosis. In 
children with severe retardation, however, there is a much greater chance of making a 
diagnosis. The most common identifiable causes of severe retardation in Western countries 
are the congenital group of disorders that include chromosomal disorders and prenatal 
toxins. In Malaysia, perinatal problems were considered to be one of the commonest 
causes although no specific data were available. 
In developed countries, the most common diagnoses are fragile X syndrome, Down 
syndrome and fetal alcohol syndrome which, together account for about one third of all 
identifiable cases of mental retardation (Batshaw, 1993). For the other two thirds, 
diagnostic studies are done based on historical information and physical findings. A child 
with an unusual appearance or multiple anomalies should be referred to a genetic center for 
consultation. On the other hand, a child with loss of milestones may have an inborn error 
of metabolism, which requires metabolic screening. 
Reber ( 1992) suggested that it is essential to pursue an etiologic diagnosis in cases of 
mental retardation in order to: 
1. identifY treatable medical conditions 
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2. provide adequate explanation to families regarding the disorder to help them cope 
with the feelings of anger, guilt and blame 
3. provide databases that will detennine the direction of the country's health, 
educational and social services 
4. identifY all associated handicapping features of the individual's disorder. 
The causes of mental retardation can be divided into several categories (The Association of 
Retarded Children of the United States, 2001 ): 
a. Genetic conditions 
Mental retardation results from abnonnality of genes inherited from parents, or 
disorders of the genes that occur during pregnancy caused by infections, over-
exposure to radiations and other factors. Inborn errors of metabolism such as 
Phenylketonuria (PKU), fall into this category and shall be dealt with in detail later 
part of this introduction. 
b. Problems during pregnancy 
Use of alcohol or drugs by pregnant mothers can cause mental retardation. 
Malnutrition, rubella infection, glandular disorders, diabetes and many other 
illnesses of the mother during pregnancy can result in a child being born with 
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mental retardation. Physical malformations of the brain and mv infection 
originating in prenatal life may also result in mental retardation. 
c. Problems at birth 
Although any birth condition of unusual stress may injure the infant's brain, 
prematurity and low birth weight causes serious problems more often than any 
other conditions especially in developing countries. 
d. Problems after birth 
Childhood diseases such as whooping cough, chicken pox and measles which, can 
lead to meningitis and encephalitis, can damage the brain. Accidents such as a blow 
to the head or near drowning can also cause mental retardation. 
e. Poverty and cultural deprivation 
Children from poor families may become mentally retarded because of 
malnutrition, disease-producing conditions, inadequate medical care and 
environmental health. Children from disadvantaged areas may also be deprived of 
many common cultural and day-to-day exposures experienced by other youngsters. 
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Intensified and advance research have produced significant results and provided methods 
and means of preventing mental retardation by identifYing and categorizing specific causes 
for the retardation. For example, 250 cases of PKU and 1000 cases of congenital 
hypothyroidism were prevented from becoming mentally retarded annually. This was 
achieved by effective newborn screenings and dietary and honnone replacement 
(Alexander, 1998). 
l.liNBORN ERRORS OF METABOLISM AND MENTAL RETARDATION 
Over 300 human diseases due to IEM are recognized and the number is constantly 
increasing as new concepts and techniques are available for identifYing biochemical 
phenotypes (Scriver, 1995). Many of these disorders remain undetected or misdiagnosed. 
Making a clinical diagnosis of ffiM is difficult because individual inborn errors are 
relatively rare and many physicians failed to consider them in acute situation until more 
common conditions have been ruled out. 
A large number of mM give rise to neurological symptoms, developmental delay and 
mental retardation. Surveys of large and representative groups of mentally retarded people 
indicate that genetically detennined metabolic disorders are the cause of 3-7% of severe 
mental retardation (Jakab, 1982). Diagnosis is complicated by the fact that there may be 
more than a thousand separate disorders that can cause mental retardation. At present, there 
are two major ways of diagnosing genetic disorders associated with mental retardation; by 
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mass screening programmes such as newborn screening programmes for treatable 
metabolic diseases like PKU and hypothyroidism, and a high index of clinical suspicion 
with expert laboratory services. Current advances in screening technology have allowed 
several hundreds of diagnoses to be made. 
Most IEM are autosomal recessive mode of inheritance. Majority of the IBM are due to 
single mutation with all other processes function normally. This often resulted in the 
children having a normal physical appearance. Abnormal appearance in IEM usually 
develop postnatally comparative to chromosomal disorders, which are present at birth. For 
example, in mucopolysaccharidosis, there is a gradual postnatal accumulation of 
polysaccharide in skin, visceral organs and bones due to genetically detennined deficiency 
of one specific enzyme. The abnormal facies manifested in the affected children is a 
progressive postnatal phenomenon related to the extent of polysaccharide accumulation. 
Meanwhile, progressive loss of mental and neurological functions becomes evident within 
the first few months after birth. 
1.2.1 PREVALENCE OF IEM WITH MENTAL RETARDATION 
There are many genetic metabolic disorders associated with mental retardation of which 
hypothyroidism and PKU are the two most common. The prevalence of some genetic 
metabolic disorders that associated with mental retardation are listed Table 1.2 (Scriver, 
1995). 
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Some of the diseases are prevalent in specific ethnic groups, such as Gaucher disease and 
Tay-Sachs disease that are most prevalent in the Ashkenazi Jews than in general or other 
populations. To date, there are no available data in Malaysia regarding genetic metabolic 
diseases. There has also been no study done looking into IEM as the aetiology for mental 
retardation. Therefore, the prevalence in general Malaysian population and its relationship 
with specific ethnic groups are still obscured. 
Table 1.2 Prevalence of genetic metabolic diseases associated with mental retardation. 
Diseases Prevalence 
Congenital hypothyroidism 1:3 500 
Phenylketonuria 1:10 000 
Sanfilippo syndrome 1:24 000 
Metachromatic leukodystrophy 1:100 000 
Fabry, s disease 1:40 000 
Gaucher disease (Ashkenazi Jews) 1:2 500 
Tay-Sachs disease (Ashkenazi Jews) 1:3 000 
(General population) 1:300 000 
Hunter syndrome 1:70 000 
Galactosemia 1:35 000 
Hurler syndrome 1:100 000 
Maple syrup urine disease 1:180 000 
Homocystinuria 1:40 000 
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1.3 PHENYLKETONURIA (PKU) 
1.3.1 HISTORICAL PERSPECTIVES 
Phenylketonuria (PKU) is an IEM. It is a rare but treatable genetic disorder. The first IEM 
was actually discovered in 1810 by Wallaston when he found a substance in the bladder 
stones of his patients. However,. it was only in 1902 that this substance was identified 
chemically as an amino acid, and named cystein. Sir Archibald Garrod later grouped 
together diseases like alcaptonuria, albinism, pentosuria and cystinuria as ffiM. Since then,. 
the number of these inherited diseases recognized had risen, including PKU. Some of these 
IEM are treatable and it is usually necessary to recognize them in early infancy to prevent 
irreversible damage to various organs such as brain, liver, kidneys and eyes. 
The incidence of PKU varies with countries and ethnic groups from rare, to relatively 
common. Though rare conditions would not normally attract much attention, PKU is an 
exception since it is a treatable genetic disease. Researchers have gone to great details in 
generating genetic knowledge and methods of treatment for this inborn error. PKU 
screening is already being carried out on virtually all newborns in every American State, 
Canada, Australia, New Zealand, Japan and many other countries throughout the world 
(Paul, 2000). 
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1.3.2 EPIDEMIOLOGICAL DESCRIPTIONS 
The worldwide incidence of PKU is 1:6000 - 1:78000 live birth. Although PKU has 
traditionally been considered more prevalent among Caucasians with 1: 10000 -15000 live 
birth (Therell, Jr., 1993), exceptions occur that may indicate ethnic composition is the 
predominant factor that influence incidence. 
The incidence of classical PKU of 1:5300 has been reported in Scotland and Ireland, while 
the reported incidence in Canada was 1:22000 (Aldis et a/. 1993). More variant exist 
among the Asian population, with incidence reported in Japan and China were 1: 120000 
and 1:20000 live birth, respectively (Aldis et al. 1993). However, the prevalence among 
mentally retarded children is higher. Studies conducted in Taiwan and Kuwait reported an 
incidence rate of 1:270 - 1:362 mentally retarded children, and 7 cases among 451 
institutionalized mentally retarded persons, respectively (Teebi eta/. 1987). 
1.3.3 CLINICAL FEATURES 
Phenylketonuria (PKU) carries serious clinical consequences to the affected neonates or 
young infants that include mild or severe mental retardation, physical handicap and even 
fatality. Nmety percent of the patients with severe mental retardation had an IQ of less than 
so (Pau~ 2000). Features other than mental retardation include a 'mousy' odor, light 
pigmentation, peculiarities of gait, abnormal stance and sitting posture, eczema and 
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epilepsy. Cataracts and brain calcification are two manifestations frequently overlooked in 
untreated classic PKU. Fortunately, mental retardation can be prevented if newborns are 
placed on a special diet from which most of the phenylalanine has been removed. Early 
diagnosis for this disorder has proven very effective in treatment or management of the 
disease (Rashed et a!. 1997). 
1.3.4 BIOCHEMICAL FEATURES 
In general, the defect in PKU is due to impaired ability to convert phenylalanine to 
tyrosine. This causes toxic accumulation of phenylalanine and its metabolites such as 
phenylpyruvate, leading to phenylketonuria and phenylacetate. The defect can be divided 
into 3 groups; defects in Phenylalanine hydroxylase, defiency in Dihyropterine reductase 
and disturbed de novo tetrahydrobiopterin biosynthesis 
Phenylalanine Tetrahydrobiopterin (BH4) 
Tyrosine Quinonoid dihydrobiopterin 
Figure I. 1 . Metabolic pathway of phenylalanine 
NAD 
Dihydropteridine 
reductase 
NADH + H 
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The commonest type of PKU associated with mental retardation is deficiency in the 
Phenylalanine hydroxylase causing hyperphenylalaninaemia, known as classical or 
typical PKU. Classical PKU is characterized by plasma phenylalanine concentration of 
more than 20 mg/dL or higher, on free diet with low or nonnal concentration of tyrosine. 
They have less than 1% normal activity of Phenylalanine hydroxylase. Now there are at 
least six mutant alleles, which have been recognized for the hydroxylase locus at 
chromosome 12q22 - q24.1, all of which are associated with the classical phenotype 
(Aldis et al 1993). 
Based on current laboratory and clinical findings, there are a lot of heterogeneity to 
Phenylalanine dehydroxylase disorders. It is now apparent that there are variant forms of 
abnormal phenylalanine metabolism, which do not result in mental retardation. These 
conditions are referred to as persistent benign hyperphenylalaninemias with plasma 
phenylalanine levels below 10 mgldL on a nonnal diet with over 5% of nonnal enzyme 
activity (Guttier and Lou, 1990). 
Other serious defect in phenylalanine metabolism involves the production of 
tetrahydrobiopterin (B~), the cofactor required for phenylalanine hydroxylation. 
Defective production of B}4 or deficiency of enzyme dihydropteridine reductase is also 
associated with abnonnal neurological development due to impaired synthesis of certain 
neurotransmitter precursor. They are referred to as malignant hyperphenylalaninemias and 
have poor prognosis compared to classical PKU. 
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1.3.4.1 Biochemical mechanism of PKU 
When Phenylalanine hydroxylase is deficient, alternate pathways are used to metabolize 
phenylalanine (Figure 1.2). Phenylalanine is transaminated to phenylpyruvic acid, which is 
reduced to phenyllactic acid. Phenylalanine can also be decarboxylated to phenylacetic 
acid, which is then conjugated to phenylacetylglutamine. These derivatives are produced in 
excess and appear in the urine. However, the derivatives of phenylalanine are not found to 
be toxic in humans. Therefore, the probable cause for neurotoxicity is the phenylalanine 
itself 
a-ketoglutarate ~lutamate 
Phenylalanine Phenylpyruvic acid Phenylacetic acid 
t I I 
Tyrosine Phenyllactic acid Phenylacetylglutamine 
Figure 1.2. Metabolism of phenylalanine. Phenylalanine hydroxylase is the site of defect in 
PKU. The compounds accumulate as a consequence of the defect. 
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. The pathogenesis of neurotoxicity can be considered from three viewpoints: 
1. Deficiency of tyrosine in the brain. Tyrosine is needed for neurotransmitter 
synthesis in the brain. 
2. Effects of phenylalanine on transport and distribution of metabolites in brain. 
Competition between large neutral amino acids such as tyrosine, tryptophan, 
leucine, isoleucine, valine and phenylalanine occurs in the brain transport system. 
Elevated levels of phenylalanine impair the uptake of other amino acids into brain. 
3. Effects on neurochemical process. Elevated phenylalanine impairs protein synthesis 
in the brain. The effect is attributed to polysome disaggregation and inhibition of 
translation initiation. 
1.3.5 DIAGNOSIS OF PKU 
In PKU, screening is done initially and the goal is to identify infants with 
hyperphenylalaninemia. Subsequently, diagnostic tests are performed to identify the 
phenotype in the particular infant. There are three levels of test in PKU; test at the 
metabolite level, test at the enzyme level and DNA analysis. 
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1.3.5.1 Tests at metabolite level 
1. Measurement of phenylalanine 
Phenylalanine levels are estimated in whole blood or plasma samples. The normal 
values are <lSOIJM in neonate and < 1201JM in older subjects. 
2. Measurement of phenylalanine metabolites 
Phenylpyruvate, a byproduct of phenylalanine can be measured. However, there is 
a fourfold interindividual variation in the substrate (phenylalanine) concentration in 
plasma at which the ketoacid is produced in PKU patients. 
3. Phenylalanine loading test 
This test is not recommended in newborns. In adults, three days of protein feeding 
at normal levels is used to classify the phenotype. 
4. Plasma phenylalanine response to B~ 
The B}4 can be given orally, or through intravenous infusion, which is more 
reliable. The phenylalanine level must be elevated prior to the test and a fall 
indicates BH.t deficiency. 
5. Pterin metabolites 
Previously, total pterin activity was assayed based on its cofactor effect on 
phenylalanine hydroxylation in-vitro. The activity is high in untreated cases of 
18 
hyperphenylalaninemia with intact B~ synthesis. Now, pterin metabolites can be 
measured directly by several methods, and one of the most widely used measures 
total neopterin and biopterin. The amounts and normal values are age-dependent. 
6. Neurotransmitter metabolites 
Tyrosine and tryptophan derivatives levels are depressed m BiLJ synthesis 
disorders. 
1.3.5.2 Tests At Enzyme Level 
1. Phenylalanine hydroxylase (P AH) 
Direct measurement of P AH activity requires liver biopsy. In vivo assay by means 
of isotopic infusions are now feasible. 
2. Dihydropteridine reductase 
Activity of this enzyme is measured in many tissues, including liver biopsy 
material, cultured skin fibroblasts and amniocytes, erythrocytes, leukocytes, 
platelets and dried blood spots on filter paper. 
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1.3.5.3 DNA Analysis 
DNA samples from venous blood, dried blood spots, buccal cells and cultured skin 
fibroblasts can be analyzed for mutations.A positive finding does not necessarily indicate a 
mutation that impairs P AH activity nor does a negative finding exclude a mutation of 
clinical significance, since no single method detects all possible mutations. 
1.3.6 CLINICAL MANAGEMENT 
Treatment with low phenylalanine diets should start soon after birth and continued 
indefinitely. Frequent monitoring is required as phenylalanine is an essential amino acid, 
and improper therapy can be fatal. In certain countries such as the United States, specific 
formulae for the diet management and expert nutritional supervision are available through 
the metabolic programme. 
Studies have also been done on the possibility of gene therapy for PKU. Reviews on the 
current state of gene therapy for PKU showed that of the three basic steps required, two 
have been accomplished; eDNA clone expressing human Phenylalanine hydroxylase, and a 
phenylalanine hydroxylase-deficient animal model. The third step, establishment of vectors 
for efficient gene transfer in-vivo is yet to be developed (Eissensmith et al. 1996). 
Recombinant adenoviral vectors, although completely successful in short term, did not 
persist beyond a few weeks due to an immune response against the adenoviral vector. 
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1.3. 7 SCREENING PROGRAM 
In 1953~ Bickel reported an effective dietary treatment for reducing brain damage resulting 
from PKU and suggested that early detection coupled with restricted phenylalanine intake 
might prevent mental retardation. From this finding, greater emphasis was put on early 
detection and treatment~ which later led to infant screening for PKU. Initially the "wet 
diaper'' test was petfonned as a preliminary screening technique. The principle of this ''wet 
diaper'' test was that any excessive phenylpyruvic acid, a byproduct in the metabolism of 
phenylalanine excreted in urine, produced a green colour change in the presence of ferric 
chloride. 
Then in early 1960s, mass screening of newborns for PKU was facilitated by Guthrie's 
development of a simple, effective laboratory procedure. The test was called the bacterial 
inhibition assay (BIA), and may be perfonned on specimens collected on filter papers. The 
Guthrie's method of bacterial testing for phenylalanine and other metabolites created a 
practical and accurate technique for screening neonates. Blood collected and transported on 
filter papers is stable, easily transported and causes minimal inconvenience to medical 
personnel, parents and infants. Once collected, the filter paper of newborn specimen is 
potentially available for other additional test procedures including DNA analysis (Aldis et 
a/. 1993). 
The concept of 'early diagnosis' in the field of inborn metabolic errors is not limited to 
routine screening of every newborn. It also includes selective screening for metabolic 
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diseases in newborns with severe acidosis, coma, seizure and other symptoms. The concept 
of early diagnosis has also been expanded to prenatal period, using methods such as 
amniocentesis, chorion biopsy and fetoscopy with fetal blood sampling. Early clinical 
diagnosis should remain closely linked to laboratory diagnosis and the practical importance 
of early diagnosis is in the timely start of treatment (Bickel, 1987). 
1.3.7.1 Reasons for screening 
Screening for PKU by measurement of phenylalanine level on dried blood spot specimen is 
recommended for all newborns prior to discharge from nursery. Infants who are tested 
before 24 hours of age should receive a repeat screening test at two weeks of age by which 
time the infants would have consumed full protein milk. The benefits of the screening 
programme are as follows: 
a. Benefit to the individual 
In PKU, treatment is optimally effective if started soon after birth and before the 
clinical manifestations of the disease. If not treated during infancy, most infants 
with PKU develop severe irreversible mental retardation. With routine screening 
and early treatment, clinical manifestations rarely developed and over 95% of the 
children develop to normal or near normal intelligence (Feldman, 1993). 
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b. Benefit to the family 
Early diagnosis may benefit the family by reducing stresses caused by a long period 
of not knowing what is wrong with the infant. The scope of early diagnosis 
prepares the family for genetic counseling and family planning. Neonatal screening 
programme also prevents the birth of further affected children. 
c. Benefit to society 
Newborn screening may have financial advantages in diseases that often result in a 
chronically sick child with a delayed diagnosis. Any possible saving may be seen 
as a benefit to society. The expense of screening and treatment is far less than the 
costs of health care of a handicapped person who may well have a normal life span 
(Holto~ 1988). In Manchester, screening for PKU and treatment of early diagnosed 
patients were calculated for one year of screening and the result showed that the 
cost of screening and treatment for these patients were much less than those whom 
did not receive treatment (Komrower, 1980). 
The calculation of the cost and benefits of screening for PKU and treatment of the 
early diagnosed patients as done by Komrower (1980) is here described. In 1978, 
eight patients suffering from PKU were detected among 59200 newborn babies 
screened by paper chromatography, giving the incidence of 1:7 400. The total 
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screening costs were 3 7 pence per test, screening by paper chromatography being 
more expensive than by Guthrie's BIA. Calculated on a very comprehensive basis, 
total costs of diagnosis, treatment, hospital visits and schooling for ten years of the 
eight patients detected by screening amount to £230000. 
The costs of care for six untreated patients with PKU living an average of 45 years 
are about £760000. These calculations were done on the assumption that two of the 
eight patients detected by screening will not receive special schooling and 
residential care. One might die before the age of 5 years and one might not develop 
severe mental retardation, suffering from mild hyperphenylalaninemia instead of 
classical phenylketonuria. Considering all these facts the benefit of one year of 
screening in Manchester area amounts to £53000 which, would raise the benefit 
considerably. 
Table 1.3. Costs of care of six untreated PKU patients in Manchester, England. 
Age of the patients (years) Place of Rehabilitation Costs(£) 
0-4 Home 
5-14: 6 x 10 patient-years at £1500 per-annum Home & special school 
15-45: 6 x 31 patient-years at £3600 per-annum Residential care 
Total 
Note: The calculation was for costs of an average length of life of 45 years. 
90000 
669 600 
759600 
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1.3. 7.2 The Efficacy of Screening Test 
Blood phenylalanine determination using the Guthrie test has been the principal screening 
test for PKU for three decades. Although well designed evaluation on sensitivity and 
specificity of the Guthrie test have never been performed, sensitivity estimates and 
international experience with its use in millions of newborns suggests that the probability 
for producing false negative results is rare. 
False positive as well as false negative results can occur in PKU screening. The ratio of 
false positive to true positive in certain situations and population conditions is as high as 
32 to I. 8. False positives have been viewed as less important than false negative results 
because they can be corrected easily whereas false negative results would cause fatal 
outcome. 
1.3.8 OTHER NEWBORN SCREENING PROGRAMMES 
Newborn screening programmes have expanded to include many other inherited disorders 
such as Maple Syrup Urine disease (MSUD), Homocystinuria (HCU), Hypothyroidism 
and Histedinemia (HE). However PKU remains the most popular treatable metabolic 
disorder included in screening panels. 
